Virus inactivation of plasma-derived proteins by pasteurization in the presence of guanidine hydrochloride

Transfusion

Volumn 41, Issue 3, 2001, Pages 382-389

  Schlegel, Andreas ^a,b   Immelmann, Andreas ^a,b   Kempf, Christoph ^a,b  

^a ZLB Bioplasma AG   (Switzerland)

^b Analysis GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; GUANIDINE; PLASMA PROTEIN;

ANIMAL CELL; ARTICLE; BLOOD TRANSFUSION; NONHUMAN; PARVOVIRUS; PASTEURIZATION; PICORNAVIRUS; PROTEIN ISOLATION; VERO CELL; VIRUS INACTIVATION;

ANIMALS; APOLIPOPROTEIN A-I; BLOOD; BLOOD SEDIMENTATION; CELL LINE; CERCOPITHECUS AETHIOPS; ENTEROVIRUS; GUANIDINE; KINETICS; MINUTE VIRUS OF MICE; OSMOLAR CONCENTRATION; SERUM ALBUMIN; STERILIZATION; TEMPERATURE; VERO CELLS; VIRION; VIRUS ACTIVATION; VIRUSES;

EID: 0035086770     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41030382.x     Document Type: Article

References (28)

1. Virus inactivation in blood
2. Pasteurization of antihemophilic factor and model virus inactivation studies
3. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration
4. Determination of adequate moisture content for efficient dry-heat viral inactivation in lyophilized factor VIII by loss on drying and by near infrared spectroscopy
5. Iodine-mediated inactivation of lipid- and nonlipid-enveloped viruses in human antithrombin III concentrate
6. New methods for inactivation of lipid-enveloped and non-enveloped viruses
7. Inactivation of viruses by β-propiolactone in human cryo poor plasma and IgG concentrates
8. Comparison of two different methods for inactivation of viruses in serum
9. Virucidal treatment of blood protein products with UVC radiation
10. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates
11. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications
12. Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia
13. Virus inactivation by pepsin treatment at pH 4 of IgG solutions: Factors affecting the rate of virus inactivation
14. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
15. Bundesgesundheitsamt und Paul-Ehrlich-Institut bundesamt für sera und impfstoffe. Bekanntmachung über die zulassung von arzneimitteln
16. Improved safety from plasma derivatives: Purification and viral elimination characteristics of Mononine
17. Conformational alteration of Sindbis virion glycoproteins induced by heat, reducing agents, or low pH
18. Picornaviridae: The viruses and their replication
19. Effects of temperature and lipophilic agents on poliovirus formation and RNA synthesis in a cell-free system
20. The transfusion-associated transmission of parvovirus B19
21. Intraand extracellular modifications of apolipoproteins
22. Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products
23. A multicenter pharmaco-surveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A
24. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: Implications for efficiency and consistency of removal of B19 DNA during manufacture
25. Molecular cloning and characterization of a novel DNA virus (TTV) associated with posttransfusion hepatitis of unknown etiology
26. Identification of a novel GC-rich 113-nucleotide region to complete the circular, single-stranded DNA genome of TT virus, the first human circovirus
27. Infection with TT virus, a novel transfusion-transmissible DNA virus, in haemophiliacs and in blood products